美国1CellBiO公司、法国巴斯德研究所和巴黎第九大学等研究人员合作利用液滴微流控技术实现单细胞水平的抗体筛选与测序。

研究提出了一种高通量方法，可用于分泌IgG原代细胞的单细胞筛选，从而表征能够结合可溶性以及膜结合抗原的抗体。CelliGO是一种液滴微流控系统，结合了高通量的IgG活性筛选（使用基于荧光的液滴内单细胞生物测定法）和配对的抗体V基因测序（液滴内单细胞条形码反转录）。

 研究分析了用疫苗靶标、多功能酶或膜结合癌靶标免疫的小鼠细胞中IgG的库多样性、克隆扩增和体细胞超突变。用这些抗原免疫后，每只小鼠产生100–1000个IgG序列。

 研究从确定的序列中生成了77种重组抗体，并发现其中93％识别可溶性抗原，14%识别膜抗原。该平台还能够从约2200个分泌IgG的活化人记忆B细胞（离体活化）中获得约450-900个IgG序列，进而证明了其用途广泛。

挖掘浆细胞和成浆细胞的抗体库可以发现用于治疗或研究的抗体。

附：英文原文

Title: High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Author: Annabelle Grard, Adam Woolfe, Guillaume Mottet, Marcel Reichen, Carlos Castrillon, Vera Menrath, Sami Ellouze, Adeline Poitou, Raphal Doineau, Luis Briseno-Roa, Pablo Canales-Herrerias, Pascaline Mary, Gregory Rose, Charina Ortega, Matthieu Delinc, Sosthene Essono, Bin Jia, Bruno Iannascoli, Odile Richard-Le Goff, Roshan Kumar, Samantha N. Stewart, Yannick Pousse, Bingqing Shen, Kevin Grosselin, Baptiste Saudemont, Antoine Sautel-Caill, Alexei Godina, Scott McNamara, Klaus Eyer, Gal A. Millot, Jean Baudry, Patrick England, Clment Nizak, Allan Jensen, Andrew D. Griffiths, Pierre Bruhns, Colin Brenan

Issue&Volume: 2020-03-30

Abstract: Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1. We present a method for high-throughput, single-cell screening of IgG-secreting primary cells to characterize antibody binding to soluble and membrane-bound antigens. CelliGO is a droplet microfluidics system that combines high-throughput screening for IgG activity, using fluorescence-based in-droplet single-cell bioassays2, with sequencing of paired antibody V genes, using in-droplet single-cell barcoded reverse transcription. We analyzed IgG repertoire diversity, clonal expansion and somatic hypermutation in cells from mice immunized with a vaccine target, a multifunctional enzyme or a membrane-bound cancer target. Immunization with these antigens yielded 100–1,000 IgG sequences per mouse. We generated 77 recombinant antibodies from the identified sequences and found that 93% recognized the soluble antigen and 14% the membrane antigen. The platform also allowed recovery of ~450–900 IgG sequences from ~2,200 IgG-secreting activated human memory B cells, activated ex vivo, demonstrating its versatility.

DOI: 10.1038/s41587-020-0466-7

Source: https://www.nature.com/articles/s41587-020-0466-7